Referencias
Documentos regulatorios, literatura revisada por pares, registros de ensayos y recursos oficiales
Documentos regulatorios
-
FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma
Publicaciones
-
Daraxonrasib versus chemotherapy in previously treated metastatic pancreatic cancer (RASolute 302)
-
Daraxonrasib in previously treated RAS-mutant non-small-cell lung cancer: phase 1/2 results
Registros de ensayos
-
RASolute 302: Phase 3 study of daraxonrasib vs. standard of care chemotherapy in previously treated metastatic PDAC
-
RASolve 301: Study of daraxonrasib in patients with RAS mutated NSCLC
-
RMC-6236-001: First-in-human study of RMC-6236 in RAS-mutant solid tumors
Sitios oficiales
-
Sitio web oficial de Revolution Medicines
-
Buscador de ensayos clínicos de Revolution Medicines
Noticias
-
Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial
-
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib
-
Daraxonrasib Nearly Doubles Survival in Previously Treated Metastatic Pancreatic Cancer